Moreover, several studies have shown that applying current guidelines for genetic testing may lead to overlook some proportion of BRCA mutation carriers and suggest that besides a positive family history of cancer or early age of diagnosis, receptor triple negativity should be considered in the guidelines for genetic analysis of BRCA1 and BRCA2 [15–18]. This evidence concerns the gene BRCA1 and cancer.